The effect of acclydine in chronic fatigue syndrome: a randomized controlled trial.

ABSTRACT:

Objectives

It is unclear whether insulin-like growth factor (IGF) function is involved in the pathophysiology of chronic fatigue syndrome (CFS). Unpublished data and reports in patient organization newsletters suggest that Acclydine, a food supplement, could be effective in the treatment of CFS by increasing biologically active IGF1 levels. Here we aimed to measure the IGF1 and IGF binding protein (IGFBP) 3 status of CFS patients compared to age- and gender-matched neighborhood controls, and to assess the effect of Acclydine on fatigue severity, functional impairment, and biologically active IGF1 level (IGFBP3/IGF1 ratio).

Design

A randomized, placebo-controlled, double-blind clinical trial.

Setting

Radboud University Nijmegen Medical Centre, The Netherlands.

Parti

SUBMITTER: The GK 

PROVIDER: S-EPMC1876596 | biostudies-literature | 2007 May

REPOSITORIES: biostudies-literature